Patent ID: 8900819
Filing Date: 2014-12-02
Classification: C12Q

Abstract:
1. A method for identifying risk of prostate cancer recurrence in a prostate cancer patient, comprising: a) detecting the level of expression of Adrenergic Receptor, Beta 2 (ADRB2) polypeptide compared to normal expression of ADRB2 polypeptide in a prostate cancer biopsy sample from a patient diagnosed with prostate cancer by detecting the binding of an antibody that specifically binds to an ADRB2 polypeptide using an immunoassay; b) comparing the level of expression of ADRB2 polypeptide in said sample to the level in a sample of normal prostate tissue; and c) identifying said patient as being at risk of recurrence of prostate cancer when said expression level is decreased relative to the level in normal prostate tissue.